{"entity":{"id":"nct03431350","kind":"trial","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","aka":["QUEST"],"tldr":"A phase 2 trial of Niraparib, Cetrelimab, Abiraterone acetate and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT03431350 by Janssen Research & Development, LLC, with 136 participants enrolled, started 2018-03-02 and due to reach its primary completion in 2021-08-31. Interventions recorded: Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg and Prednisone 5 mg. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT03431350","url":"https://clinicaltrials.gov/study/NCT03431350"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["parp-inhibitor"],"targets":[],"drugs":["niraparib","cetrelimab","abiraterone","prednisone"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03431350","phase":"2","setting":"A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","sponsor":"Janssen Research & Development, LLC","started":"2018-03-02","startedType":"actual","yearReported":2023,"enrolled":136,"enrolledBasis":"registry","outcomes":[{"endpoint":"Combination 1: Part 2: Objective Response Rate (ORR)","primary":true,"unit":"%","arms":[{"name":"Combination 1: Part 2 (Dose Expansion): Cohort 1A: BM+: Niraparib 200 mg + Cetrelimab 480 mg","n":21,"value":23.8,"note":"95% CI 9.9 to 43.7; Figures from the ClinicalTrials.gov results section (first posted 2023-11-18), not from a publication"},{"name":"Combination 1: Part 2 (Dose Expansion): Cohort 1B: BM-: Niraparib 200 mg + Cetrelimab 480 mg","n":11,"value":9.1,"note":"95% CI 0.5 to 36.4"}],"source":"https://clinicaltrials.gov/study/NCT03431350?tab=results"}]},"route":"/trials/nct03431350/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"cetrelimab","kind":"drug","name":"Cetrelimab","route":"/drugs/cetrelimab/"},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}